Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Sep 20, 2018-- Two Oral Presentations Highlighting Previously Reported Phase 2b STORM Data in Patients with Penta-Refractory Multiple Myeloma and Phase 2b SADAL Data in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma --
NEWTON, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced two oral presentations and one poster...
-
Sep 13, 2018-- Oral Selinexor Achieves 26.2% Overall Response Rate and Duration of Response of 4.4 Months in Overall Study Population; Responses Typically Occurred Within 1 Cycle (4 Weeks) of Treatment --
NEWTON, Mass., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that updated clinical data from the Phase 2b...
-
Sep 4, 2018
NEWTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of Karyopharm’
-
Sep 4, 2018-- Current Chief Executive Officer of Abeona Therapeutics, Inc. and former Executive Vice President and Chief Commercial Officer of Alexion Pharmaceuticals, Inc.; Brings Wealth of Leadership and Global Strategic Experience --
NEWTON, Mass., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Carsten Thiel, Ph.D., to...
-
Aug 29, 2018
NEWTON, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management...
-
Aug 28, 2018-- Oral Selinexor Achieves 25.4% Overall Response Rate and DOR of 4.4 Months in Overall Study Population --
NEWTON, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that clinical data from the Phase 2b STORM...
-
Aug 7, 2018-- Completed Rolling Submission of a New Drug Application to FDA Seeking Accelerated Approval for Selinexor As a New Treatment for Patients with Penta-Refractory Multiple Myeloma --
NEWTON, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the second quarter 2018...
-
Aug 6, 2018-- Company to Host Conference Call to Discuss Second Quarter 2018 Financial Results and Recent Business Developments on Tuesday, August 7, 2018 at 8:30 a.m. ET --
NEWTON, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the completion of the rolling submission of a...
-
Aug 3, 2018
NEWTON, Mass., Aug. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Aug 2, 2018
NEWTON, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the Company’s management...
-
Jul 31, 2018− Conference Call Scheduled for Tuesday, August 7, 2018 at 8:30 a.m. ET −
NEWTON, Mass., July 31, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report second quarter 2018...
-
Jul 25, 2018-- Formerly of Shire, MedImmune, Centocor and Pharmacia; Brings Over 20 Years of Healthcare Industry Leadership Experience --
NEWTON, Mass., July 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Ian Karp as Vice President,...
-
Jul 18, 2018-- Company Plans to Complete Submission During the Second Half of 2018 --
NEWTON, Mass., July 18, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Company has initiated a rolling...
-
Jul 2, 2018
NEWTON, Mass., July 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Jun 25, 2018-- Formerly of Chiasma, Amgen and Procter and Gamble, Brings Over 25 Years of Global Commercial Operations Leadership Experience --
NEWTON, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Anand Varadan as Executive...
-
Jun 15, 2018-- SVd Once Weekly Demonstrates 17.8-month PFS and 83% ORR in the BOSTON Multiple Myeloma (MM) Population; 63% ORR in the Overall Study Population --
NEWTON, Mass., June 15, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data...
-
Jun 1, 2018Treatment with Selinexor Prolongs Progression-Free Survival Compared to Placebo (5.5 months versus 2.7 months, respectively) in Patients with Liposarcoma
NEWTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the...
-
Jun 1, 2018
NEWTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
May 31, 2018
NEWTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive...
-
May 24, 2018-- Antengene Rights Include All Human Oncology Indications for Selinexor, Eltanexor and KPT-9274, and Non-Oncology Human Indications for Verdinexor --
NEWTON, Mass. and SHANGHAI, China, May 24, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) (Karyopharm) and Antengene Corporation (Antengene), today announced their entry into...
-
May 17, 2018Three Posters Highlighting Updated Data from the STOMP Arms Evaluating Selinexor and Dexamethasone in Combination with Velcade®, Pomalyst®, or Darzalex® in Relapsed or Refractory Multiple Myeloma
NEWTON, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that three posters highlighting clinical data...
-
May 16, 2018A Total of Four Posters Highlighting Selinexor Data in Hematologic and Solid Tumor Malignancies Will Be Presented at the Meeting
NEWTON, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that four posters will be presented at the upcoming
-
May 10, 2018-- Oral selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma --
NEWTON, Mass., May 10, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the first quarter 2018 and...
-
May 7, 2018
NEWTON, Mass., May 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the closing of its previously announced...
-
May 4, 2018
NEWTON, Mass., May 04, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
May 3, 2018-- Conference Call Scheduled for Thursday, May 10, 2018 at 8:30 a.m. ET --
NEWTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report first quarter 2018...
-
May 2, 2018
NEWTON, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the pricing of its previously announced...
-
Apr 30, 2018- Oral Selinexor Achieves 25.4% Overall Response Rate and Median Duration of Response of 4.4 Months in Patients with Penta-Refractory Myeloma -
NEWTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported positive top-line results from the Phase 2b...
-
Apr 10, 2018
NEWTON, Mass., April 10, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the U.S. Food and Drug Administration...
-
Apr 2, 2018
NEWTON, Mass., April 02, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Mar 19, 2018Five Posters Highlighting Selinexor Data, Including in Combinations with Zejula® (niraparib) in Ovarian Cancer and Velcade® (bortezomib) in Neuroblastoma
NEWTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that eight posters will be presented at the...
-
Mar 15, 2018− Phase 2b STORM Study Evaluating Selinexor in Patients with Penta-Refractory Myeloma Remains on Track; Top-Line Data Expected end of April 2018 –
NEWTON, Mass., March 15, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the fourth quarter and...
-
Mar 8, 2018Conference Call Scheduled for Thursday, March 15, 2018 at 8:30 a.m. ET
NEWTON, Mass., March 08, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report fourth quarter and year...
-
Mar 1, 2018
NEWTON, Mass., March 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Feb 7, 2018
NEWTON, Mass., Feb. 07, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that members of the management team will...
-
Feb 1, 2018
NEWTON, Mass., Feb. 01, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that the Compensation Committee of...
-
Jan 31, 2018
NORWALK, Conn. and NEWTON, Mass., Jan. 31, 2018 (GLOBE NEWSWIRE) -- The Multiple Myeloma Research Foundation (MMRF), the world’s number one private funder of multiple myeloma research, and...
-
Jan 25, 2018− Biogen Brings Expertise in Development and Commercialization of Products for Neurological and Neurodegenerative Diseases –
NEWTON, Mass., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (NASDAQ:KPTI) today announced its entry into an agreement for Biogen to acquire Karyopharm’s investigational oral...
-
Jan 3, 2018
NEWTON, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Dec 10, 2017− Data Provide Further Evidence of Tolerability with Robust Anti-Myeloma Activity When Selinexor is Combined with Velcade, Pomalyst, Revlimid or Darzalex —
NEWTON, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of four posters highlighting...
-
Dec 10, 2017− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma —
NEWTON, Mass., Dec. 10, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the presentation of Phase 1/2 clinical data...
-
Nov 13, 2017
NEWTON, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Nov 7, 2017− Recent Utilization of ATM Financing Facility Nets Proceeds of $47 million; Extends Cash Runway to end of 2018, Beyond STORM Expansion Data Readout —
NEWTON, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2016...
-
Nov 3, 2017
NEWTON, Mass., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief...
-
Nov 2, 2017− Company Completes Exclusive Licensing Transaction Valued at Up To $193 Million Plus Royalties with Ono Pharmaceutical Co. Ltd. for Selinexor and KPT-8602 In Japan and Certain Other Countries in Asia —
NEWTON, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported financial results for the third quarter 2017...
-
Nov 1, 2017Fourteen Abstracts Selected, Including Three Oral Presentations
NEWTON, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that 14 abstracts have been selected for...
-
Oct 26, 2017
NEWTON, Mass., Oct. 26, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, announced today that it will report third quarter 2017...
-
Oct 12, 2017− ONO Rights Include Oncology Indications for Selinexor and KPT-8602 in Japan, South Korea, Taiwan, Hong Kong and ASEAN countries —
NEWTON, Mass. and OSAKA, Japan, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI) (Karyopharm) and Ono Pharmaceutical Co., Ltd. (ONO), today announced their entry into...
-
Sep 20, 2017— The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death —
NEWTON, Mass., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today reported a successful outcome from the Phase 2 portion...
-
Sep 12, 2017— Michael Falvey, Formerly an Executive at Millennium Pharmaceuticals, Seven Bridges Genomics, Ahura Scientific, and Aspect Medical Systems, Brings 35 Years of Financial and Operational Experience at High Growth Companies —
NEWTON, Mass., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced the appointment of Michael Falvey as...